NEWS FROM USA
NDA Approvals
|
Approval Date |
Drug |
NDA Sponsor |
Brand Name |
Prescribing information |
|
19 Oct 2018 |
Levoleucovorin Injection |
Spectrum Pharms |
Khapzory |
Earlier approved Levoleucovorin was calcium salt |
ANDA Approvals
|
Approval Date |
Drug Product |
ANDA Sponsor |
Corresponding RLD |
Number Of Other Approved Generics |
|
17 Oct 2018 |
Breckenridge Pharm |
Prevacid (Takeda) |
Thirteen |
|
|
17 Oct 2018 |
Taro |
Epiduo Forte (Galderma) |
None |
|
|
17 Oct 2018 |
Qilu Pharm |
N/A |
Five |
|
|
17 Oct 2018 |
Qilu Pharm |
N/A |
Six |
|
|
17 Oct 2018 |
Amneal Pharms |
Isuprel (Hospira) |
Three |
|
|
18 Oct 2018 |
Hisun Pharm |
Capastat Sulfate (Akorn) |
One (Mylan) |
|
|
18 Oct 2018 |
Accord Hlthcare |
Diamox (Teva) |
Four |
|
|
18 Oct 2018 |
Sandoz |
Levophed (Hospira) |
Four |
|
|
20 Oct 2018 |
Strides |
Neurontin (Pfizer) |
Fifteen |
|
|
22 Oct 2018 |
West-Ward Pharma |
Onfi (Lundbeck) All the generics were approved on the same date as Onfi’s ODE expired on 21 Oct 2018 |
Eight |
|
|
22 Oct 2018 |
Bionpharma |
Four |
||
|
22 Oct 2018 |
Bionpharma |
Eight |
||
|
22 Oct 2018 |
Breckenridge |
Eight |
||
|
22 Oct 2018 |
Taro Pharm |
Eight |
||
|
22 Oct 2018 |
Upsher-Smith |
Eight |
||
|
22 Oct 2018 |
West-Ward |
Four |
||
|
22 Oct 2018 |
Amneal |
Eight |
||
|
22 Oct 2018 |
Hetero Labs |
Eight |
||
|
22 Oct 2018 |
Piramal |
Eight |
||
|
22 Oct 2018 |
Amneal |
Four |
||
|
22 Oct 2018 |
Upsher |
Four |
||
|
22 Oct 2018 |
Mylan |
Four |
||
|
22 Oct 2018 |
Zydus |
Eight |
||
|
22 Oct 2018 |
Lupin |
Triamcinolone Acetonide Ointment (Mylan) |
Eleven |
*Highlighted products are the 1st generics approval for the corresponding RLD
Tentative ANDA Approvals
|
Approval Date |
Drug |
Company |
|
12 Oct 2018 |
Alogliptin |
Alembic |
|
12 Oct 2018 |
Mifepristone |
Teva |
|
15 Oct 2018 |
Benzoyl Peroxide;Clindamycin Phosphate |
Tolmar |
|
16 Oct 2018 |
Fesoterodine Fumarate |
Torrent |
|
16 Oct 2018 |
Colchicine |
Zydus |
|
19 Oct 2018 |
Tadalafil |
Amneal |
NEW GENERICS LAUNCHES IN US
|
DRUG |
COMPANY |
Corresponding RLD |
Annual sales quoted in press release as per IQVIA |
Press Release |
|
Medroxyprogesterone Acetate Injectable Suspension |
Mylan |
Depo-Provera (Pfizer) |
$ 181 Million |
|
|
Isoproterenol Hydrochloride |
Amneal |
Isuprel (HOSPIRA ) |
$158 Million |
|
|
Carmustine |
Amneal |
BiCNU (Emcure) |
$84 Million |
|
|
Clobazam Tablets |
Amneal |
Onfi (Lundbeck) |
$594 Million |
|
|
Clobazam Tablets |
Camber (Hetero) |
Onfi (Lundbeck) |
$594 Million |
|
|
Clobazam Tablets |
Bionpharma |
Onfi (Lundbeck) |
$594 Million |
Link |
|
Clobazam Suspension |
Amneal |
Onfi (Lundbeck) |
$255 Million |
|
|
Clobazam Suspension |
Bion pharma |
Onfi (Lundbeck) |
$255 Million |
Link |
USFDA INSPECTION
Lupin's Pithampur Unit-3 (Indore) Inspected by US FDA
NEWS FROM EUROPE
Positive CHMP opinions (EMA)
|
Drug |
Sponsor |
Indication |
|
Lupin |
Myotonia In Non-Dystrophic Myotonic Disorders |
|
|
Vertex Pharma |
Treat Patients With Cystic Fibrosis Aged 12 to <24 Months |
Other News from Europe
· Mylan and Biocon Announce Positive CHMP Opinion for Ogivri, Biosimilar Trastuzumab
· Mylan Launches Hulio (Biosimilar Adalimumab) in Markets Across Europe
Now, you can also follow us on twitter @pharmacaptions. If you have any query/suggestion then please write us at pharmacaption@gmail.com
No comments:
Post a Comment